Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects With Symptomatic Early Hip Osteoarthritis

NCT05276011 is registered in ClinicalTrials.gov with Kolon TissueGene, Inc. as lead sponsor.

NCT NCT05276011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05276011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects With Symptomatic Early Hip Osteoarthritis
Lead sponsor
Kolon TissueGene, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2027
Completion date
October 31, 2028
Enrollment
255 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative osteoarthritis